B.Pharm

STELIS Biopharma Pvt. Ltd. is a fully-owned subsidiary of Strides set up in 2013 to consolidate and augment the R&D activities of Inbiopro, which was fully acquired in 2012; and in extending the value chain to manufacturing and commercialisation of the product pipeline.   STELIS is pursuing a blended strategy of-  developing both ‘biosimilars’ and ‘novel biotherapeutics’ to a ‘Regulated’ market (US/EU) standard for global markets. Our strategy is to offer high-quality bio-pharmaceuticals at affordable prices initially in high-growth Emerging Markets whose vast patient populations offer un-paralleled opportunities for expanded access.

Lantech Pharmaceuticals Ltd. was established in August 2008, with a vision to become a global supplier of Active Pharma Ingredients and Intermediates. With its manufacturing site spread over 42 acres. with several reaction capabilities, Lantech has been retained as a reliable and preferred supplier by many multi-national pharmaceutical companies.

Medreich facilities have received the seal of approval from leading global regulatory bodies such as -UK MHRA, Australia TGA, SA MCC, Health Canada, and French AFSSAP, GCC, PIC, regulatory bodies of various countries in the African continent and independent bodies like UNICEF and MSF.

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries.

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries. They have helped over 800 clients to develop and launch some of the most important drugs and devices of our time-helping people live better and healthier lives everywhere in the world. Headquartered near Boston, Massachusetts, PAREXEL operates in more than 50 countries around the world.

Post : Clinical Research Associate II

Jamjoom Pharma launched the commercial operations in the year 2000 in Saudi Arabia. The company has consistently maintained a track record of rapid growth and expansion and has established itself as one of the fastest growing companies in the  region consisting of Middle East, Africa and CIS countries.    In Saudi Arabia, The company is ranked among the Top 5 Pharma Companies. Following the outstanding success in Saudi Arabia the company rapidly spread its operations to other countries in the region. The international operation is also growing rapidly and the  products of the company are available in many countries of the region.

Post : Medical Representative

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries. They have helped over 800 clients to develop and launch some of the most important drugs and devices of our time-helping people live better and healthier lives everywhere in the world. Headquartered near Boston, Massachusetts, PAREXEL operates in more than 50 countries around the world.

Post : Drug Safety Associate

Alembic Limited, with an established presence in the Indian pharma  industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs1000 crores today, Alembic Limited is one of India’s leading integrated pharmaceutical companies. We continue to enjoy leadership positions in antibiotics, anti-infective, anti-cough and also have significant worldwide presence in specialty therapeutic areas such as cardiology, neurology, diabetology, etc. We have also plans for expansion in Ophthalmic etc.

Post : Executive/Sr. Executive- Validation (Gen.OSD)

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post Approval Research division.